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Abstract  18 
Kaposi sarcoma-associated herpesvirus (KSHV) has a tropism for B lymphocytes in which it 19 
establishes latency and can also cause lymphoproliferative disorders of these cells 20 
manifesting as primary effusion lymphoma (PEL) and multi-centric Castleman disease 21 
(MCD).  T cell immunity is vital for the control of KSHV infection and disease however few 22 
models of B lymphocyte infection exist to study immune recognition of such cells.  Here we 23 
developed a model of B lymphocyte infection with KSHV where infected tonsillar B 24 
lymphocytes were expanded by providing mitogenic stimuli and these challenged with 25 
KSHV-specific CD4+ T cells. Infected cells expressed viral proteins found in PELs namely 26 
LANA and vIRF3, albeit at lower levels, with similar patterns of gene expression for the 27 
major latency, vIL-6 and vIRF3 transcripts.  Despite low level expression of ORF50, 28 
transcripts for the immune evasion genes K3 and K5 were detected, with some 29 
downregulation of cell surface expressed CD86 and ICAM.  The vast majority of infected 30 
lymphocytes expressed IgM and the Igλ light chain, recapitulating these features seen in 31 
infected cells in MCD.  We assessed the ability of the infected lymphocytes to be targeted by 32 
a panel of MHC class II matched CD4+ T cells and found that LANA-specific T cells 33 
restricted to different epitopes recognized these infected cells.  Given that at least some 34 
KSHV latent antigens are thought to be poor targets for CD8+ T cells, we suggest that CD4+ 35 
T cells are potentially important effectors for the in vivo control of KSHV infected B 36 
lymphocytes. 37 
 38 
Importance 39 
KSHV establishes a latent reservoir within B lymphocytes but few models exist to study 40 
KSHV-infected B cells other than the transformed PEL cell lines which have likely accrued 41 
 
 
mutations during the transformation process.  We developed a model of KSHV-infected 42 
primary B lymphocytes which recapitulate features seen in PEL and MCD by gene 43 
expression and cell phenotype analysis, allowing the study of T cell recognition of these cells.  44 
Challenge of KSHV-infected B cells with CD4+ T cells specific for LANA, a protein 45 
expressed in all KSHV-infected cells and malignancies in vivo, showed that these effectors 46 
could efficiently recognize such targets.  Given the virus expresses immune evasion genes or 47 
use proteins with intrinsic properties such as LANA that minimize epitope recognition by 48 
CD8+ T cells, CD4+ T cell immunity to KSHV may be important for maintaining the virus 49 
host balance. 50 
  51 
 
 
Introduction 52 
Kaposi sarcoma-associated herpesvirus (KSHV) is one of the two human γ-herpesviruses 53 
with oncogenic potential.  This virus has a tropism for endothelial cells where it is associated 54 
with the development of Kaposi sarcoma (KS), as well as being tropic for B lymphocytes 55 
where it can cause primary effusion lymphoma (PEL) and multi-centric Castleman disease 56 
(MCD) (1).  The immune response is important for control of KSHV infection as infected 57 
patients whose cellular immune response is suppressed either for transplantation or due to 58 
untreated HIV infection are at an increased risk of developing KS.  Importantly in these 59 
scenarios if immune competence is restored through relaxation of immunosuppression or 60 
administration of highly active anti-retroviral therapy respectively, regression of KS lesions 61 
can be seen, implying an important role for the T cell response in control of the virus and 62 
malignancies (2, 3). 63 
KSHV is known to infect CD19+ B lymphocytes (4), but little is known how KSHV-specific 64 
T cell control is exercised over infected B lymphocytes.  The only model which has been 65 
used to examine  T cell recognition of infected B lymphocytes comes from studies using PEL 66 
derived lines as targets.  Here CD8+ T lymphocytes were unable to recognize reporter 67 
antigens expressed in PELs thought to be related to their low expression of the transporter 68 
associated with antigen processing-1 mRNA, disrupting antigen presentation to these 69 
effectors (5).  CD4+ T cells specific to the genome maintenance protein LANA, a protein 70 
expressed in all infected cells and malignancies, in most cases showed poor if any recognition 71 
of PELs (6).  This was a consequence of expression of the KSHV gene vIRF3 which, 72 
amongst other functions, inhibits expression of the MHC class II transcriptional transactivator 73 
CIITA; a protein required for the expression of class II and other genes in this antigen 74 
processing pathway (7).  Although these studies are performed on cell lines derived from 75 
 
 
patients with disease, these lines have likely accrued mutations and may not resemble B cells 76 
which the virus maintains latency in. The ability of KSHV-specific T lymphocytes to respond 77 
to KSHV infected non-transformed B lymphocytes which are likely to have intact antigen 78 
processing pathways is so far largely untested.  79 
Several models of primary B cell infection have been developed to study KSHV infection in 80 
these cells.  Initial studies used CD40 ligand stimulation of B cells to make them receptive to 81 
infection (8), while others have co-cultured B lymphocytes with virus producer cells to allow 82 
direct cell to cell virus transfer, or exposed B lymphocytes to concentrated preparations of 83 
KSHV (9-12).  Such in vitro infected cells express latent transcripts and transiently express 84 
selected lytic transcripts and genes, inducing some proliferation of the infected cells but 85 
unlike the related γ-herpesvirus Epstein-Barr virus (EBV), does not lead to transformation 86 
(10).  These models have been informative for studying which cytokines may be induced by 87 
infection (13) and examining the potential identity of B lymphocyte targets of KSHV, which 88 
are likely IgM+ CD27+ Igλ using cells (10).   89 
However the analysis of immune recognition of ex vivo infected B cells has been limited 90 
with studies suggesting that CD4+ T cells may suppress spontaneous lytic replication and 91 
encourage latency (11).  This mechanism required cell contact, the CD4+ T cells to be 92 
activated, but was independent of MHC restriction and so how such restriction might operate 93 
in vivo is not clear.  Furthermore, how ex vivo infected cells which have stably entered 94 
latency may be controlled by KSHV-specific immune effectors has not been tested.  To 95 
examine these questions we developed a KSHV B cell infection model where we expanded 96 
infected cells to ask what viral genes are expressed in infected cells, how infection may 97 
modulate immune receptor expression and whether antigen-specific T cells can recognize 98 
these targets. 99 
 
 
 100 
Materials and Methods 101 
Tonsil cell preparations and infections 102 
Tonsil specimens were obtained from patients undergoing routine tonsillectomy to treat 103 
chronic tonsillitis.  Patients were adolescent or young adults and their tonsils were not 104 
inflamed at the time of surgery.  All participants gave written informed consent in accordance 105 
with the Declaration of Helsinki; ethical approval was granted from the South Birmingham 106 
Health Authority Local Research Ethics Committee.  Specimens were disaggregated to single 107 
cell suspensions by teasing apart the tissue and fine mincing.  Mononuclear cells were 108 
isolated by purification over a Lymphoprep gradient (Nycomed Pharma), as per the 109 
manufacturer’s instructions, aliquoted, cryopreserved and stored in liquid nitrogen.  DNA 110 
was isolated from an aliquot of the tonsillar cells for HLA typing by sequence specific 111 
oligonucleotide PCR analysis performed at the Anthony Nolan Trust. 112 
Tonsillar mononuclear cells were infected with KSHV using a protocol similar to one 113 
previously described (14).  Briefly rKSHV.219 infected Vero cells (VK219; (15)) transduced 114 
with a pInducer 20 lentivirus (16) engineered to express ORF50 under the control of the 115 
tetracycline promoter, or ORF50 lentivirus transduced Vero cells infected with either the 116 
BAC16 derived K5 deletion mutant or its paired revertant virus (17), were seeded in 24 well 117 
plates at 50 000 cells per well. After 24 hours, virus replication was induced for 24 hours by 118 
the addition of 2 μg/ml doxycycline and 1.25 mM sodium butyrate.  Media from these wells 119 
was then removed and 500 000 tonsillar mononuclear cells were seeded per well, centrifuged 120 
onto the VK219 monolayers and incubated for 48 hours.  Parallel mock infections of tonsillar 121 
cells were conducted by culturing these either on monolayers of VK219 cells which had been 122 
treated with 1 mM phosphonoacetic acid (18) for the previous 30 hours prior to induction and 123 
 
 
during the co-culture, or culturing the tonsillar cells in the absence of VK219 cells.  B cells 124 
were then purified from the mock and KSHV infected cultures using anti-CD19 Dynabeads 125 
(LifeTechnologies) and the beads removed using a Detachabead CD19 kit as per the 126 
manufacturer’s instructions. 127 
Purified B cells were cultured in Iscoves MEM with 100 U/ml IL-4 (Peprotech), penicillin 128 
streptomycin, gentamycin and Fungizone (Life Technologies) on monolayers of L cells 129 
transduced to express CD40L that had been γ-irradiated (10 000 rads).  After 48 hours 130 
KSHV-infected cells were selected by addition of puromycin to a final concentration of 131 
between 0.1-0.3 μg/ml.  B cells were expanded, moved to fresh L cell monolayers weekly 132 
and maintained under puromycin selection.   133 
Presence of contaminating VK219 cells in the B lymphocyte cultures was determined by 134 
performing semi-quantitative end point PCR assays on 25 ng of DNA extracted from the 135 
cultures.  The PCR assay detected the neomycin resistance gene encoded by the ORF50 136 
lentivirus used to transduce the VK219 cells. Primers used were neo forward AGG ATC TCC 137 
TGT CAT CTC ACC TTG CTC CTG and neo reverse AAG AAC TCG TCA AGA AGG 138 
CGA TAG AAG GCG.  As controls, transduced VK219 cells were mixed with BJAB cells to 139 
give 0.1% and 0.01% VK219 cells and DNA extracted from these mixtures.  These controls 140 
and DNA from the samples was subject to PCR amplification using different numbers of 141 
cycles to detect products.  142 
B cell surface marker expression was assessed by staining cells with antibodies specific to 143 
HLA class I, HLA-DR, CD20, CD54, CD86 or appropriate isotype control antibodies 144 
(Biolegend).  Igλ and Igκ expression was assessed by staining cells with biotinylated 145 
antibodies specific to these proteins (Southern Biotech) and these detected by incubating with 146 
avidin conjugated APC-Cy7 (Biolegend).  Cells were fixed in 2% paraformaldehyde 147 
 
 
(eBioscience), analyzed on an LSRII flow cytometer (Becton Dickinson) and data processed 148 
using Flowjo (Treestar). 149 
Immunofluorescence staining for LANA protein expression in KSHV infected B cells 150 
Established KSHV infected or mock infected B cell lines were assayed for LANA protein 151 
expression by immunofluorescence staining.  Cell suspensions were washed in phosphate 152 
buffered saline (PBS), dried onto microscope slides and fixed in cold acetone for 10 minutes.  153 
Slides were then dried, washed in PBS and stained with either an isotype control rat antibody 154 
or a LANA-specific rat antibody (clone LN 53, Advanced Biotechnologies) for 1 hour at 155 
37oC.  Slides were washed four times and bound antibody detected using an anti-rat Alexa 156 
568 conjugated antibody (Life Technologies) and incubating for 1 hour at 37oC.  Slides were 157 
then washed and examined using a Nikon E600 microscope fitted with epifluorescence 158 
detection. 159 
Western blot analysis 160 
Cells were lysed in 9M urea with 0.075 M Tris HCl, pH 7.5, sonicated and lysates clarified 161 
by centrifugation.  Protein concentrations were determined by Bradford assay (Bio-Rad 162 
Laboratories) and 20 μg of protein separated by SDS-PAGE and transferred onto 163 
nitrocellulose membranes using standard techniques.  Blots were probed with antibodies 164 
specific for LANA (clone LN53), vIRF3 (CM-A807, Abcam) and actin (AC-74, Sigma-165 
Aldrich).  Bound antibodies were detected using the appropriate anti-species peroxidase 166 
labelled antibody, followed by detection using an ECL kit (GE Healthcare).  167 
Measurement of viral transcripts 168 
Total RNA was extracted from cells using a NucleoSpin RNA II kit (Macherey Nagel) 169 
according to the manufacturer’s instructions. An aliquot (1µg) was treated with DNAse I 170 
 
 
(Life Technologies) to remove residual genomic DNA, before being reverse-transcribed 171 
using Qscript (VWR).    172 
Selected KSHV transcripts were quantified by Taqman qRT-PCR  using the primer and probe 173 
combinations shown in Table 1.  Primer and probe sequences were designed using Primer 174 
Express 3.0 (Life Technologies) and were based on the BC-1 KSHV genome sequence 175 
(accession number U75698).  Primer-probe combinations were selected to avoid known 176 
KSHV sequence polymorphisms and assays to detect spliced transcripts were designed to 177 
span exon-exon junctions. All Taqman probes (Eurogentec) were modified with FAM and 178 
TAMRA at the 5′ and 3′ ends, respectively. Cellular GAPDH mRNA, used as an internal 179 
control, was detected using a VIC-labelled commercial assay (Life Technologies, 4310884E).  180 
Amplification reactions were prepared in a final volume of 25 µl containing 1 x Taqman 181 
Universal MasterMix II (Life Technologies), 300 nM forward and reverse primers, 200 nM 182 
probe, 0.5 µl GAPDH reagent and 5 µl cDNA. PCR amplifications were performed using an 183 
ABI 7500 with default thermocycling conditions. All test samples were run in duplicate, 184 
while template-negative and RT-negative samples served as controls. To determine the 185 
absolute levels of KSHV and GAPDH transcripts, serial dilutions from 1 – 105 copies of a 186 
plasmid (AQ2) were included in each PCR experiment and used to generate appropriate 187 
standard curves. AQ2 was derived from the AQ plasmid (19) by the insertion of a 188 
commercially synthesised 1093 bp sequence carrying the contiguous KSHV amplicons 189 
(GenScript). All data were analysed using Sequence Detection Software v2.0 (Applied 190 
Biosystems) and are reported as copies relative to GAPDH.   191 
Comparisons of gene expression levels between PELs and infected B lymphocytes were 192 
performed using the R statistical program (v 3.0.2) (20) on log10 transformed mean values so 193 
these were normally distributed as judged using the Shapiro-Wilk test.  These transformed 194 
 
 
values were then subjected to two sample t-tests to determine differences in transcript levels 195 
between PEL lines and infected lymphocytes. 196 
KSHV genome loads 197 
DNA was extracted from cells using a NucleoSpin Tissue kit (Macherey Nagel) and viral 198 
genome loads determined by qPCR. KSHV DNA was detected using the vIL-6 primer-probe 199 
combination while cellular beta 2 microglobulin (B2m), used as an internal control,  was 200 
detected using published primers (21). Serial dilutions of AQ2 plasmid and BJAB DNA were 201 
used to generate standard curves for vIL6 and B2m, respectively. Data are expressed as 202 
KSHV genome copies per cell, assuming two B2m genes per diploid cell. 203 
T cells and recognition experiments 204 
The ability of T cells to recognize KSHV infected targets was performed as described 205 
previously, using established T cell clones  (6).  Briefly, triplicate cultures of 5000 T cells 206 
were incubated with 50 000 target cells which were either KSHV-infected or mock infected 207 
target B cells, or B cells sensitized with the T cells cognate synthetic peptide-epitope 208 
(Mimotopes).  Cells were incubated in RPMI-1640 10% FCS for 18 hours and supernatants 209 
then harvested from these cultures and assayed for IFN-γ by ELISA (Endogen). 210 
  211 
 
 
Results 212 
KSHV infection of primary B cells and their propagation. 213 
In a preliminary set of experiments we determined whether we could infect tonsillar derived 214 
B cells with rKSHV.219 virus.  Unfractionated tonsillar mononuclear cells were infected with 215 
KSHV by incubating on monolayers of Vero cells which contained latent rKSHV.219 that 216 
had been treated 24 hours previously to induce virus replication.  As a mock infection, 217 
parallel aliquots of tonsillar cells were incubated on monolayers of induced VK219 cells 218 
which had been treated for the previous 30 hours with phosphonoacetic acid to inhibit virus 219 
production.   After 48 hours co-culture, CD19 expressing B cells were selected, cultured for 220 
72 hours to allow GFP expression from the rKSHV.219 genome, and the proportion of 221 
infected cells identified by flow cytometry.  Figure 1 shows two representative results of such 222 
infections from tonsillectomy patients T46 and T7.  Consistent with previous reports (9) we 223 
found that these cells could be infected at a low percentage; typically GFP expressing cells 224 
would be detected in the range of 0.5-1.6% of B cells. 225 
We next asked whether the infected cells could be expanded by in vitro culture.  Previous 226 
studies had shown that unlike the related γ-herpesvirus Epstein-Barr virus (EBV), ex vivo 227 
infection of B cells with KSHV does not lead to transformation of the B cells (9) but induces 228 
some limited proliferation (10).  To expand the population of B cells, we delivered a 229 
mitogenic stimulus to them by incubating these on CD40-ligand expressing L cells in the 230 
presence of IL-4.  As rKSHV.219 virus encodes a puromycin resistance gene, we enriched 231 
for infected B cells by selection with puromycin.  We found that the infected cells were very 232 
sensitive to puromycin requiring low doses to enrich these cells which did not obviously 233 
affect L cell viability.  However compared to mock infected B cells cultured in parallel 234 
without puromycin, the infected cells grew slowly, doubling every 4-5 days as compared to 235 
 
 
the parallel uninfected B cells which doubled every 72 hours.  All subsequent experiments 236 
used cells which had undergone at least three to four weeks of selection, which contained 237 
between 5% to 50% GFP expressing cells.  The presence of contaminating VK219 cells was 238 
examined using a semi-quantitative PCR assay to detect the neomycin resistance gene 239 
encoded by the ORF50 expressing lentivirus used to transduce these cells.  Only DNA 240 
extracted from lines derived from two of nine lines, T44b and T48, had detectable sequence 241 
at levels less than 0.01% of the population (data not shown). B cell lines could be maintained 242 
for a similar length of time compared to mock infected cells, typically for up to 12 weeks, 243 
with some lasting >20 weeks.  During passaging of these cells we monitored for RFP 244 
expression, a gene in rKSHV.219 expressed under the control of the PAN promoter,  as a 245 
marker of lytic cycle replication and observed few cells, usually less than 5%, expressing this 246 
marker in the cultures.  To confirm that the B cells were infected with rKSHV.219, we 247 
purified these by FACS for GFP expression and conducted immunofluoresecence assays on 248 
these cells staining for LANA.  Figure 2 shows representative results from one of three sorts, 249 
showing the characteristic punctate staining of LANA, reminiscent of the pattern seen in 250 
primary effusion lymphomas (22), indicating these KSHV infected cells could be expanded 251 
in vitro.   252 
 253 
Antigen and gene expression of KSHV infected primary B cells 254 
In the next series of experiments we sought to determine which KSHV genes were expressed 255 
in the infected B cells, principally to identify which could be used as immunological targets 256 
and also monitor any immune evasion gene expression.  We focused on likely latent genes 257 
and their products as we observed few RFP expressing cells in our established cultures, 258 
suggesting no substantial spontaneous lytic reactivation was occurring. Western blot analysis 259 
 
 
was performed on lysates from two tonsillar preparations of rKSHV.219 infected B cells 260 
which had been FACS sorted to 90% purity or mock infected B cells maintained on CD40-261 
ligand and IL-4 in parallel.  As a control, a lysate from the PEL JSC-1, from which 262 
rKSHV.219 was derived was used.  Blots were initially probed with antibodies to vCyclin 263 
and vFLIP however no expression of these proteins was detected in the JSC-1 or any B cell 264 
lysates, nor could we detect expression of the EBV protein EBNA1, found in approximately 265 
80% of PEL lines, in infected B lymphocyte lysates (data not shown).  Blots were then 266 
sequentially probed for LANA, vIRF3 and actin, the latter as a loading control, and results 267 
shown in Figure 3.  Infected B cells demonstrated expression of LANA, although at levels 268 
lower  than seen in JSC-1, while vIRF3 expression in the infected B cells was substantially 269 
lower than that in the PELs.  270 
To further characterize these infected B cells we measured viral transcript expression by 271 
qRT-PCR using a panel of Taqman based assays we developed.  These included the splice 272 
variants of transcripts from the major latency locus driven from the constitutive promoter as 273 
shown in Figure 4A (23, 24), namely the tricistronic mRNA encoding LANA, vCyclin and 274 
vFLIP, the bicistronic mRNA encoding vCyclin and vFLIP and the monocistronic mRNA 275 
encoding vFLIP.  Specificity of assays which detect spliced transcripts was confirmed by 276 
testing against unspliced (genomic) DNA which showed no detection using the bicistronic 277 
vCyclin vFLIP assay and weak detection using the monocistronic vFLIP assay, giving a 278 
background of 0.13% compared to the unspliced tricistronic message.  Assays measuring the 279 
PEL expressed vIRF3 and vIL-6 mRNAs were also developed as were assays for three lytic 280 
cycle expressed genes including the immediate early expressed lytic switch gene ORF50 281 
(RTA) and two early expressed mRNAs K3 and K5.   The location of the amplicons within 282 
the genome, primer and probe sequences are shown in Table 1.  To validate these assays we 283 
tested them on RNA extracted from the PELs BC-1, JSC-1, BCBL-1, VG-1, and BC-3.  All 284 
 
 
assays were compared to a standard which was a synthetic plasmid containing the PCR 285 
amplicons, thereby allowing absolute quantitation of transcript levels within a cell type.   286 
Figure 4B (left panels) shows results of qRT-PCR assays reporting results relative to GAPDH 287 
expression, grouping transcripts into either those expressed from the latency locus (LANA, 288 
vCyclin, vFLIP), PEL specific transcripts (vIRF3 and vIL-6) and lytic transcripts (ORF50, 289 
K3 and K5).  Latency locus transcripts showed in most cases that the tricistronic transcript 290 
was the most abundant followed by the bicistronic transcript, the exception being BC-1 where 291 
this pattern was reversed.  Previous northern blot analysis of BC-1 has showed a consistent 292 
profile as to what we detected, but some contrast for BCBL-1, where northern analysis 293 
indicated the bicistronic transcript to be more abundant than the tricistronic message (23, 25).  294 
What dictates splicing of these RNAs is unknown and so why this difference has occurred is 295 
not clear, but may relate to drift in gene expression patterns in cultured cells over time or be 296 
related to the culture conditions used in our experiments.  Interestingly the BCP-1 PEL, not 297 
analyzed in our experiments, by northern analysis showed a similar pattern of transcript 298 
expression as to what we have detected in most PELs with the tricistronic more abundant 299 
than the bicistronic message (26).  Low level expression of the monocistronic transcript was 300 
detected, consistent with previous findings (24).  All PELs expressed vIL-6 RNA, usually at 301 
high levels compared to other transcripts, and all expressed vIRF3.  In most cases low levels 302 
of the ORF50 transcript were detected but perhaps surprisingly, transcripts for the early 303 
expressed K3 and K5 genes were detected.   304 
We next performed these qRT-PCR assays on RNA extracted from the infected B cells which 305 
had been enriched for infection by selection with puromycin.  These cells showed different 306 
levels of KSHV infection as judged by GFP expression, thus: T3 90%, T10 90%, T13 75%, 307 
T14 43%, T32 51%, T42 62%, T44a 51%, T44b 54% and T48 29%.  To account for these 308 
variations and allow comparison of transcript levels between the different infected cells and 309 
 
 
PELs, we corrected transcript levels to 100% GFP expression.  Figure 4B (right panels) 310 
shows results of transcript levels in these cells where patterns of transcript expression showed 311 
similarities to what was seen in the PELs.  Thus the tricistronic was the most abundant of the 312 
latency locus transcripts, followed by the bicistronic with very low levels of the 313 
monocistronic transcripts detected.  The vIL-6 transcripts were again the most abundant 314 
detected, while there was lower and variable expression of vIRF3.  Low levels of ORF50 315 
transcript were detected, consistent with our observation of few if any RFP expressing cells 316 
in the cultures.  However similar to the PEL data, some expression of K3 and K5 transcripts 317 
was detected in the infected B cells.  Statistical analysis comparing individual transcript 318 
levels between PELs and infected lymphocytes showed that only the tricistronic transcript 319 
showed a significant difference between the two cell types (t-test, p=0.023).  Overall, the 320 
pattern of transcript level in the infected B cells broadly recapitulated what was detected in 321 
the PELs. 322 
PEL cell lines are known to harbor high frequencies of KSHV genomes so using our qPCR 323 
assays we quantified genome load per cell in the infected B cells and compared these levels 324 
to what we observed in PELs.  Figure 4C shows results of these assays.  PELs contained 325 
variable but high levels of genomes with BC-3 containing over 600 copies of the genome, 326 
while JSC-1, BCBL-1 and BC-1 had lower yet substantial frequencies of genomes, being 327 
between 145 to 244 copies per cell.  These values were comparable to those previously 328 
reported using a similar methodology on these cell lines (27).  Interestingly in repeated assays 329 
on VG-1 DNA only two copies of the genome per cell were detected.  Analysis of genome 330 
loads of infected B cells, corrected for frequency of GFP expressing cells, showed these had 331 
lower frequencies as compared to most PELs in five of seven lines analyzed, while lines 332 
derived from donors T10 and T44a showed comparable or greater  copies of genomes.  A 333 
second independently established line from this donor, T44b, showed levels closer to the 334 
 
 
other infected cells.  These findings suggest that that the infected B cells maintain similar or 335 
reduced genome loads as compared to PELs. 336 
 337 
Cell surface phenotype analysis of infected B cells 338 
We next examined the B cells to identify phenotypic markers associated with infection and 339 
whether there was evidence of altered immunological marker expression.  Firstly the identity 340 
surface immunoglobulin heavy and light chain expression was determined as in MCD, KSHV 341 
is found in IgM positive λ light chain expressing cells (28).  Here purified B cells which had 342 
been exposed to the virus producer cells and then cultured for 72 hours to allow GFP 343 
expression were stained for surface expression of Igλ and IgM.  Figure 5A shows flow 344 
cytometry results of this analysis, where GFP negative uninfected cells showed there was 345 
split expression of Igλ and Igκ (not shown) and that the majority of the population expressed 346 
IgM. By contrast, few GFP positive cells showed Igκ expression (data not shown), however 347 
there was a marked if not exclusive preference for co-expression of Igλ and IgM by the 348 
infected cells.  Figure 5B shows a similar analysis of established B cell lines which had been 349 
maintained for more than 5 months.  Mock infected cell lines contained both Igλ and Igκ (not 350 
shown) expressing cells, however there were few IgM expressing cells in these cultures.  The 351 
KSHV infected cells however showed little evidence of Igκ expression (not shown) but 352 
expressed Igλ and had maintained their expression of IgM, indicating that culturing these 353 
cells in this fashion recapitulates phenotypic features seen in KSHV disease states. 354 
KSHV encodes genes such as K3, K5 and vIRF3 which can modulate cell surface expression 355 
of molecules which immune effectors recognize or receive co-stimulatory signals from (7, 356 
29-32).  As such we determined the cell surface expression of HLA class I, class II, and the 357 
 
 
co-stimulatory molecules CD86 and CD54 (ICAM) on infected cells which had undergone 358 
enrichment by puromycin selection and compared expression to co-resident uninfected cells 359 
within the culture by flow cytometric analysis.  Despite expression of K3 transcripts in 360 
infected cells (Figure 4), no obvious modulation of this proteins target, namely surface HLA 361 
class I, was observed (Figure 6A).  Similarly infected cells showed little change in surface 362 
levels of HLA class II as compared to uninfected cells, despite the presence of vIRF3 363 
transcripts.   364 
Analysis of T lymphocyte costimulatory marker expression is presented in Figure 6B where 365 
compared to uninfected cells, infected cells had reduced surface levels of CD86 and CD54.  366 
Such a profile is consistent with expression of the K5 gene as measured in the qRT-PCR 367 
analysis, whose product has ubiquitin ligase activity which induces endocytosis of these 368 
proteins.  To test whether K5 was responsible for the downregulation of these markers, B 369 
cells were infected with a recombinant KSHV in which the K5 gene was deleted (K5Δ) or a 370 
derivative of this virus in which the K5 gene is restored (K5R) (17).  Cells were selected and 371 
surface marker analysis conducted as before; Figure 6C shows CD86 and CD54 surface 372 
expression analysis results of one of three pairs of lines infected with the K5Δ or K5R 373 
viruses.  Cells infected with the K5Δ virus showed substantial but not complete restoration of 374 
surface CD86 and CD54 expression as compared to co-resident uninfected cells, suggesting 375 
that K5 expression alters at least some surface markers on infected cells in this model.  376 
 377 
Recognition of KSHV infected B cells with KSHV-specific CD4+ T cells 378 
As we had demonstrated that the KSHV-infected cells expressed LANA RNA and protein, 379 
but did not appear to obviously modulate MHC class II cell surface expression, we 380 
determined whether these infected cells could be targeted by a panel of LANA-specific CD4+ 381 
 
 
T cells.  We were especially interested in the ability of CD4+ T cells to recognize this antigen 382 
as it is expressed in all infected cells in vivo and the repeat sequences within LANA have 383 
been shown to decrease presentation of epitopes to CD8+ T cells (33, 34).  For these 384 
experiments we HLA-typed the infected B cells and challenged these with HLA matched 385 
CD4+ T cell clones specific for LANA which we had previously established (6).  A total of 386 
six T cell clones were used, three of which were responsive to the HLA-DQ6 presented 387 
peptides LAPSTLRSLRKRRLSSPQGP (LAP/LRS), EYRYVLRTSPPHRPG (EYR) or 388 
PAFVSSPTLPVAPIP (PAF), two clones which were specific for the HLA-DR13 presented 389 
peptides LRSLRKRRLSSPQGP (LRS) or GDDLHLQPRRKHVAD (GDD), and one 390 
responsive to the HLA-DQ7 presented peptide GSPTVFTSGLPAFVS (GSP).  Here the 391 
clones were incubated with either the infected B cells, mock infected B cells or mock infected 392 
B cells sensitized with the T cells cognate peptide, for 18 hours and recognition assessed by 393 
measuring IFN-γ secretion from the T cells.  Figure 7 shows representative results  from three 394 
assays, where the effectors were challenged with  B cell lines infected with KSHV or mock 395 
infected lines that had been maintained on CD40L and IL-4 in parallel.  T7 and T31 KSHV-396 
infected targets were 68% and 93% GFP positive respectively and these co-expressed both 397 
HLA-DR13 and HLA-DQ6, while T10 infected targets were 23% GFP positive and 398 
expressed HLA-DQ7.  In all cases we observed IFN-γ secretion from the T cells when 399 
challenged with the infected cells, indicating that despite the down regulation of cell surface 400 
co-stimulatory molecules and the low level expression of vIRF3, these KSHV LANA-401 
specific CD4+ T cells could recognize the KSHV-infected B cells. 402 
  403 
 
 
Discussion 404 
In the present study we developed a model of primary B lymphocyte infection with KSHV to 405 
examine gene expression and immune recognition of infected B cells which, unlike PEL cell 406 
lines, have not gone through a transformation process.  Infected B lymphocytes expanded 407 
with mitogenic stimuli expressed latent proteins and genes in a similar pattern to what is 408 
observed in PELs.  Phenotypically these recapitulated features of MCD infected cells namely 409 
the almost exclusive expression of IgM and Igλ by the infected cells.  Although these cells 410 
expressed genes associated with immune evasion, some of which did modulate cell surface 411 
markers, we found that the KSHV-infected cells were capable of being recognized by LANA-412 
specific CD4+ T cells. 413 
Our initial studies characterizing the KSHV-infected B cells showed that they expressed key 414 
proteins namely LANA and vIRF3, while qRT-PCR analysis indicated that a similar 415 
repertoire of genes were expressed as seen in PELs assayed in parallel. However despite 416 
finding transcripts for LANA and vIRF3 in the infected lymphocytes, the corresponding 417 
levels of protein for each were lower than the PELs, suggesting that in this model, factors 418 
other than transcript abundance affects protein levels.  We have previously found that ectopic 419 
expression of LANA or vIRF3 in model cell lines at levels similar to those in PELs is toxic 420 
(unpublished observations).  We speculate that PELs adapt to high level expression of these 421 
proteins during the transformation process and that the infected lymphocytes in the present 422 
study have not had sufficient time to adapt to high level protein expression.  Some expression 423 
of the lytic cycle assigned K3 and K5 genes was also observed, potentially related to the low 424 
level expression of ORF50.  However few cells expressed RFP, a marker of lytic cycle 425 
replication, suggesting that either these transcripts were detected from the few cells with lytic 426 
virus replication, or that these genes were being expressed outside of true lytic replication.  427 
 
 
The latter case seems most likely as all infected lymphocytes, rather than a subset, showed 428 
decreased surface expression of K5 target proteins.  Furthermore, recent transcriptome 429 
analysis of the PEL BCP-1 indicated that some transcripts, particularly K5, can be found in 430 
these cells in the absence of obvious lytic cycle replication (35).  Such expression patterns 431 
show some contrast to what has been observed in latently infected SLK cells, where there is 432 
minimal expression of K5 and modulation of its targets outside of lytic cycle replication (17).  433 
K5 expression may then have been induced in our cells due to the culture conditions used, or 434 
as PELs express this transcript, the K5 promoter may be activated in a B cell background, due 435 
to B cell specific transcription factors.  Alternatively this may be a consequence of the 436 
elevated genome loads detected as high genome loads, at least in primary infection of cells, 437 
are associated with the modulation of these cell surface immune cell stimulating ligands (36). 438 
Despite the expression of K5 and the decreased surface expression of CD86 and CD54, no 439 
obvious modulation of surface MHC class I was seen on the infected cells.  This is likely due 440 
to the apparent increased sensitivity of CD86 and CD54 to K5 as compared to MHC class I, 441 
especially certain allotypes of class I (29, 31, 37).  Turning to MHC class II expression, no 442 
obvious decrease in cell surface expression of these proteins was observed on infected cells 443 
despite the expression of vIRF3. This protein can block promoter activity of the class II 444 
transcriptional transactivator CIITA, which is required for expression of MHC class II and 445 
other genes required for the MHC class II processing pathway (7).  Although vIRF3 446 
transcript was expressed, we detected low levels of protein in infected cells compared to the 447 
JSC-1 PEL.  Interesting in this context we have previously found that BCBL-1 PELs 448 
similarly express low levels of vIRF3 protein compared to other PELs, but maintain good 449 
expression of surface MHC class II (6).   450 
Analysis of cell surface marker expression showed that the vast majority of KSHV infected 451 
cells were predominantly within the Igλ light chain IgM heavy chain subset, reminiscent of 452 
 
 
these features observed within infected cells of MCD lesions (28).  Established cultures of 453 
infected cells maintained this phenotype while parallel mock infected cultures switched 454 
immunoglobulin heavy chain isotype usage, a likely consequence of continual CD40-ligand 455 
and IL-4 stimulation, suggesting that virus infection suppresses isotype switching.  456 
Interestingly this bias of light chain usage was seen within 72 hours after virus infection. 457 
Related studies in which KSHV infection of tonsillar B lymphocytes was examined at 72 458 
hours post exposure for LANA protein expression have also shown that the vast majority of 459 
LANA expressing cells were in the Igλ using population (10). Why this bias occurs is unclear 460 
as there are no obvious functional or phenotypic differences between these two subsets.  461 
Potentially this selection may be a consequence of vFLIP expression as B cells within a 462 
transgenic vFLIP mouse model more frequently utilize this light chain (38).  In this case the 463 
ability of vFLIP to promote expression of NF-kB may be responsible, as this transcription 464 
factor is required at key stages of immature B cell development for the selection of Igλ using 465 
cells (reviewed in (39)).  However as light chain rearrangement occurs during B lymphocyte 466 
maturation in the bone marrow, the tonsillar B lymphocytes used in this study likely have 467 
already undergone light chain selection.  This may suggest that either infected cells may be 468 
converted to Igλ usage through processes such as receptor revision (40) although this may 469 
seem unlikely given the vast majority of cells are expressing this receptor by 72 hours post 470 
infection.  Alternatively Igκ using cells may not sustain infection.   471 
The T lymphocyte response is vital for effective control of KSHV infection and disease, 472 
however whether one subset of T lymphocytes, either CD4+ or CD8+, is more effective 473 
remains an open question.  This is particularly relevant when examining features of proteins 474 
such as the genome maintenance protein LANA, which is expressed in all KSHV-infected 475 
cells and malignancies, making it an attractive immunological target.  Like its related genome 476 
maintenance protein homologue in EBV, EBNA1, LANA encodes extensive repeat 477 
 
 
sequences, some of which share nucleotide homology with EBNA1.  These function to limit 478 
protein synthesis in cis and inhibit proteasomal degradation (34, 41-43).  As most CD8+ T 479 
cell epitopes appear to be derived from newly synthesized proteins which are degraded by the 480 
proteasome (44), these features of LANA have been shown to minimize CD8+ T cell 481 
recognition of model epitopes inserted into LANA (33, 34, 41).  Although LANA-specific 482 
CD8+ T cell recognition of KSHV-infected cells is untested, one may predict recognition to 483 
be minimal.  By contrast, epitope generation for CD4+ T cell recognition would not be 484 
subject to these restrictions and as B lymphocytes express class II MHC, these may be 485 
legitimate targets for LANA-specific CD4+ T cells.  Indeed we found that for all T cell 486 
specificities tested, infected cells could be recognized by the MHC matched T cell clones.  487 
The magnitude of responses are comparable to those seen in analogous experiments using 488 
EBV-specific CD4+ T cells targeting epitopes from some latent antigens such as the EBNA3 489 
proteins expressed by EBV transformed B lymphoblastoid cell lines (LCLs) (45-48).   490 
The ability of the LANA-specific CD4+ T cell clones to recognize KSHV-infected cells 491 
shows some contrast to what is seen using EBV EBNA1-specific CD4+ T cells challenged 492 
with their cognate LCL which naturally expresses EBNA1.  These effectors either do not or 493 
weakly recognize such targets (47, 49).  This is thought to be a consequence of the poor 494 
release of EBNA1 protein by LCLs, thereby restricting the ability of cells to take up antigen 495 
and re-present it to T cells, or making EBNA1 epitope presentation reliant on endogenous 496 
processing of antigen through a macroautophagy route (48, 50, 51).  We have previously 497 
shown that B cells with intact antigen processing pathways exogenously fed LANA protein 498 
can take up, process and present epitopes to LANA-specific CD4+ T cells and that such B 499 
cells can also present endogenously expressed LANA (6).  These findings suggest that 500 
LANA, despite performing a similar function and having some sequence homology to 501 
EBNA1 is processed and presented differently and may be a more relevant target for CD4 T 502 
 
 
cells as compared to EBNA1 in EBV infection.  Furthermore, we suggest that as LANA has 503 
properties which limit efficient CD8+ T cell recognition, CD4+ T cell immunity to this 504 
protein is likely to be important in control of KSHV infection and disease. 505 
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 660 
Figure legends 661 
Figure 1. Frequency of KSHV-infected B cells after ex vivo infection.  Tonsillar B cells from 662 
donors T46 and T7 were either infected with KSHV by culturing on monolayers of induced 663 
VK219 cells for 48 hours, or mock infected by culturing on induced monolayers which had 664 
been pre-treated with phosphonoacetic acid (PAA) to inhibit virus replication.  B 665 
lymphocytes were then magnetically sorted, cultured for a further 72 hours to allow 666 
expression of the GFP reporter from the rKSHV.219 genome, then stained for CD20 surface 667 
expression and the proportion of cells expressing GFP as a marker of infection determined by 668 
flow cytometry. 669 
Figure 2. Expression of LANA protein in B cell lines by immunofluorescent staining 670 
analysis.  Mock infected or KSHV-infected cells which had been established for eight weeks 671 
were stained with a LANA-specific monoclonal antibody and bound antibody detected by 672 
staining with an Alexa-fluor conjugated secondary antibody.  Antibody binding was 673 
visualized  by epifluorescence microscopy. 674 
Figure 3. Western blot analysis for detection of viral proteins in lysates from B cell lines.  675 
Proteins from lysates of the PEL JSC-1, mock infected and KSHV-infected B cell lines which 676 
had been maintained for 18 weeks were separated by PAGE and blotted onto PVDF 677 
 
 
membranes.  Blots were sequentially probed for either LANA, vIRF3 or actin.  Filled 678 
arrowheads represent specific protein detection. 679 
Figure 4. Gene expression analysis and genome load within KSHV infected cell lines.  A.  680 
Map of qPCR assays to detect splice variants driven from the constitutively active promoter 681 
of the latency locus.  Arrows represent primers and dashed lines indicate intronic regions 682 
spanned by the primers.  B. Gene expression was determined from cDNA prepared from the 683 
PEL lines BC-1, JSC-1, BCBL-1, VG-1 and BC-3 and the infected B cell lines, assayed for 684 
expression of the following transcripts: tricistronic LANA-vCyclin-vFLIP, bicistronic 685 
vCyclin-vFLIP, monocistronic vFLIP, vIL-6, vIRF3, K3, K5, ORF50 and GAPDH.  686 
Transcripts are expressed  relative to GAPDH transcript abundance.  * denotes <10-5 vFLIP 687 
transcript detected for T3 and T10.  C. Genome load was determined in DNA extracted from 688 
the above cell lines and quantified using the vIL-6 qPCR assay.  Results shown for the 689 
infected B cell lines have been corrected to represent 100% GFP expression.  Infected 690 
lymphocytes had been established for the following times: T3 18 weeks, T10 18 weeks, T13 691 
10 weeks, T14 8 weeks, T32 10 weeks, T42 12 weeks, T44a 10 weeks, T44b 8 weeks, T48 6 692 
weeks. 693 
Figure 5.  Cell surface immunoglobulin usage by KSHV-infected B lymphocytes.  A. 694 
Tonsillar cells were infected with KSHV as described in Figure 1 and stained for the 695 
expression of CD20, Igλ and IgM, followed by flow cytometry analysis.  Populations shown 696 
are gated on the CD20 GFP negative uninfected cells or CD20 GFP positive infected 697 
population.  B. B cell lines which were either mock- or KSHV-infected and maintained for 698 
twenty weeks were analyzed for cell surface expression of Igλ and IgM.  Mock infected cells 699 
are gated on viable cells, while KSHV infected cells are gated on GFP viable cells. 700 
 
 
Figure 6. Flow cytometric analysis of cell surface expressed immunological markers on 701 
KSHV-infected B cell lines.  A.  KSHV-infected B cell lines which had been established for 702 
eight weeks were stained with antibodies specific to either MHC class I or class II or an 703 
isotype control antibody (Iso) and gated on either GFP positive infected cells (KSHV) or GFP 704 
negative cells co-resident in the culture (Non). B. KSHV-infected B cell lines were stained 705 
for expression of CD86 or CD54 and gated on infected and co-resident non-infected cells as 706 
before.  C. KSHV-infected cell lines that had been established for six weeks were infected 707 
with either a K5 deleted virus (K5Δ) or a virus derived from this construct in which the K5 708 
gene was restored (K5R) and stained for expression of CD86 or CD54 on infected and co-709 
resident non-infected cells as before.  Data is representative of at least three independent cell 710 
lines for each assay. 711 
Figure 7. LANA-specific CD4+ T cell recognition of mock- or KSHV-infected B lymphocyte 712 
lines. A. KSHV-infected B cell lines or mock infected B cell lines or mock infected B cell 713 
lines sensitized with the T cells cognate peptide (Pep) derived from donors T7 and T31 which 714 
co-expressed HLA-DQ6 and HLA-DR13 were challenged with the LANA-specific HLA-715 
DQ6 restricted clones LAP/LRS, EYR, PAF or the DR13 restricted clones LRS and GDD.  B 716 
lymphocyte lines had been established for ten weeks.  B. KSHV-infected or mock infected B 717 
cell lines derived from donor T10 which expressed HLA-DQ7 were challenged with the 718 
LANA-specific HLA-DQ7 restricted clone GSP. B lymphocyte lines had been established for 719 
eight weeks.  In both cases T cell recognition of targets was assessed by measuring IFN-γ 720 
secretion.  Error bars represent the standard deviation of assay replicates. 721 







Table 1 qPCR assay primer and probe sequences with BC-1 genomic locations 
Assay Forward primer Probe Reverse primer 
LANA/ 
vCyclin/ 
vFLIP 
TTTACCTCCACCGGCACTCT 
127007-126988 
 
CACGTCTTCCTCCCCAATCCCTCC 
126974-126951 
 
GTCCCCGGAGACACAGGAT 
126927-126945 
vCyclin/ 
vFLIP 
GGTAGATGGGTCGTGAGAACACT 
123692-123714 
ACCGTCGCCGCTCCGCACTT 
123771-123752 
TCCGGCTGACTTATAAACA^AAGC 
127831-127813^123776-123773 
vFLIP TTCCACTGCCGC^CTGTAGAG 
122848-122859^123595-123602 
TGTCAGGTTCTCCCATCGACGACG 
123623-123646 
ACGGACAACGGCTAGCGTACT 
123679-123659 
vIL-6 GATGCTATGGGTGATCGATGAA 
17753-17732 
TTCCGCGACCTCTGTTACCGTACCG 
17728-17704 
GGGCTCTAGAATACCCTTGCAGAT 
17678-17701 
vIRF3 GGAGAAGACCA^AGGCCATTTG 
90952-90942^90847-90838 
TGAGGAGGATCACCCAGCCTTTTGC 
90815-90791 
CTGCGTGACCGGCACAT 
90773-90789 
ORF50 GCAAGATGACAAG^GGTAAGAAGC 
71601-73613^72572-72581 
CTGTGTGGAAAGCTTCGTCGGCCTC 
72592-72616 
TGGTAGAGTTGGGCCTTCAGTT 
72645-72624 
K3 GCGGGTTGAAGTGTTTCCAT 
19139-19120 
TCGGCCGACATCACCAGAGTGTG 
19112-19090 
TTTCCTGAAGCTCGATCTCCTCTA 
19063-19086 
K5 TCCACCCGCAGTGTTTAAGC 
26368-26349 
TGTCTCGAAACACGGCCTGTCAAATG 
26335-26310 
CGTGCGCGTGCGGTATA 
26283-26299 
^ denotes splice junction. 
